Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1606 participants.
Also called NCT04707469
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,606 participants
- Sponsor
- Registry
-
NCT04707469 -
2020-000299-39
-
- Other papers using this trial's data
- Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Bulgaria, Canada, Croatia, Czechia, Estonia, Germany, Hungary, India, Poland, Puerto Rico, Slovakia, Slovenia, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT04707469. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-15 (actual); primary completion 2023-03-07 (actual). Results posted on 2024-04-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
- Acronym
- PIONEER PLUS
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Oral semaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04707469- Content hash
fd64cb01802e846625121017e511344c5e7fffbee2657a547e1b5f5dea21f9a1